KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Amortization - Intangibles (2019 - 2025)

Bristol Myers Squibb (BMY) has disclosed Amortization - Intangibles for 7 consecutive years, with $826.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles fell 51.21% to $826.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 billion, a 62.61% decrease, with the full-year FY2025 number at $3.3 billion, down 62.61% from a year prior.
  • Amortization - Intangibles was $826.0 million for Q4 2025 at Bristol Myers Squibb, down from $831.0 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $2.5 billion in Q2 2021 to a low of $826.0 million in Q4 2025.
  • A 5-year average of $2.0 billion and a median of $2.4 billion in 2022 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: rose 10.12% in 2021, then plummeted 65.65% in 2025.
  • Bristol Myers Squibb's Amortization - Intangibles stood at $2.4 billion in 2021, then fell by 3.06% to $2.3 billion in 2022, then decreased by 2.77% to $2.3 billion in 2023, then dropped by 25.68% to $1.7 billion in 2024, then tumbled by 51.21% to $826.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Amortization - Intangibles are $826.0 million (Q4 2025), $831.0 million (Q3 2025), and $830.0 million (Q2 2025).